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The clinical benefit of antiretroviral therapy in infants is
established. In this cohort collaboration, we compare im-
munological and virological response to treatment started
before or after 3 months of age. Early initiation provides a
better short-termresponse, althoughevolutionafter 12months
of age is similar in both groups.
In the absence of combination antiretroviral therapy (cART),
approximately 20% of vertically infected children born in
developed countries progress to AIDS in the first year of life [1].
Since cART became available, early initiation of antiretroviral
therapy (ART) in infants has been questioned, and policies
have varied across Europe. The prevention of disease pro-
gression when treatment is started before the age of 3 months
was clearly demonstrated in the South African Children with
HIV Early Antiretroviral Therapy randomized trial [2] and in the
European Infant Collaboration (EIC) [3]. All guidelines have
been updated to recommend early ART in infants infected with
human immunodeficiency virus (HIV).
Vertical infection is associated with rapid viral multiplication
during the first weeks of life and high viral load (VL) over the first
2 years of life. At birth, the CD4 percentage is high and decreases
to reach a plateau around the age of 1 year [4]. CD4 T-cell
depletion associated with HIV infection is correlated with clinical
progression [1]. The level of plasma HIV RNA has a poorer
prognostic significance than CD4 percentage.
Although the clinical benefits of early treatment are recog-
nized, early initiation of cART does not prevent establishment of
a reservoir of latently infected cells. It was suggested that early
intervention during primary infection leads to better long-term
virological suppression (VS) and preserved immune system
function [5]. Indeed, when cART is started early in infancy
with persistent control of HIV replication, children may become
seronegative after the loss of maternal antibodies [5, 6]. Our aim,
within the EIC group, was to determine if virological and
immunological responses to treatment differ according to the
age at which cART is started during first 12 months of life.
METHODS
Study Population
EIC study methods have been described previously [3]. For the
present analysis, infants were excluded if they received mono-
therapy or dual therapy (n 5 38), developed AIDS before cART
was initiated (n 5 7), or did not begin treatment before the age
of 12 months (n 5 26). The final sample size was 139 infants.
A subsequent data merger collected virological and immunolog-
ical data to the end of 2008.
Variables
Demographics, pregnancy data, details of prophylaxis and
treatment, and CD4 and VL measurements available since birth
were collected. We defined cART as any regimen that included at
least 3 antiretroviral drugs. Infants were classified into 3 groups:
those starting cART at#3 months of age (0–91 days) (the early-
treatment group), those starting at ages 3–6 months, and those
starting at ages 6–12 months; the latter 2 groups were considered
the deferred-treatment group.
Baseline VL and CD4 percentages were measured before
3 months of age in both groups. This corresponded to the
pretreatment values in the early treatment group, which were
measured at a median age 37 days (interquartile range [IQR],
12–54 days) for VL and 39 days (IQR, 17–56 days) for CD4
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percentage. In the deferred treatment group, baseline values
were selected at the age closest to the median ages before age
3 months. Outcomes were VL and CD4 percentage at 6, 12, 18, 24,
and 48 months of age. As the threshold for viral detection varied
along the study period, VS was defined as VL ,500 copies/mL.
Statistical Analysis
Evolution of CD4 percentage and log10 VL from baseline to
48 months was described separately for the 3 groups, using
smoother techniques [7]. We added the reference curve of CD4
percentage by age established among HIV-exposed, uninfected
(HEU) children included in the national French Perinatal Cohort
(N 5 11 851) and the European Collaborative Study (ECS)
(N 5 1028) [8]. CD4 z scores generated from these populations
as reference were compared with zero at 6, 12, and 24 months in
early- and deferred-treatment groups.
The time from treatment initiation to first VS was estimated
in each group by the Kaplan-Meier method, censored at last
follow-up using the log-rank test for significance. A hazard ratio
for the associations with early versus deferred treatment was
estimated using the Cox model.
Levels of quantitative CD4 percentage and log10 VL, and pro-
portion of VL ,500 copies/mL at baseline and measured at
6 months (61.5 month) and 12, 18, 24, and 48 months
(63 months) were compared in the 2 groups. The v2 test, Fisher
exact test, or Monte Carlo method was used for categorical data,
and the Student t test, analysis of variance, Mann-Whitney U test,
and Kruskal-Wallis test were used for continuous data.
The analysis was intent-to-treat, using SAS (version 9.1; SAS
Institute, Cary, North Carolina) and R software (Foundation for
Statistical Computing).
RESULTS
Baseline characteristics of the 139 infants were evenly distributed
between the 3 treatment groups including cohort of origin, year
of birth, geographical origin of the mother, mode of delivery,
antenatal and postnatal ART prophylaxis, maternal VL nearest
delivery, gestational age, sex, and baseline infant CD4 cell count
and VL (Supplementary Table 1).
Immunological Response
The CD4 percentage diminished less markedly over the first year
of life in the early-treatment group compared with the deferred-
treatment groups (Figure 1a). However, CD4 percentages were
consistently lower in all groups of HIV-infected infants compared
with HEU infants, and median CD4 z score values remained
significantly lower in both early- and deferred-treatment groups at
the ages of 6, 12, and 24months (Supplementary Table 2).Median
nadir CD4 cell count and CD4 percentages were significantly
higher in the early-treatment group until the age of 6 months, but
not thereafter.
Virological Response
A lower peak VL was observed in the early-treatment group
infants compared with the 2 other groups (Figure 1b). Kaplan-
Meier survival analysis showed that time from treatment initi-
ation to first VS was significantly shorter in the early-treatment
group (crude hazard ratio [HR], 1.8 [95% confidence interval
{CI}, 1.2–2.7]; P 5 .003; HR adjusted for baseline VL and
cohort 5 1.7 [95% CI; 1.0–2.9]; P 5 .05) (Figure 1c).
Although similar at baseline, the zenith VL and median VL at
6 months were significantly lower in the early-treatment group,
compared with the deferred-treatment group. Moreover, in the
early-treatment group, the zenith VL was significantly correlated
with the starting age for cART (r 5 0.48, P , .001). There was
a trend to lower VL between 12 and 48 months in the early-
treatment group compared with the deferred-treatment group.
DISCUSSION
The prognosis of HIV-infected children has improved consid-
erably since the introduction of cART in 1996 [9]. The EIC has
demonstrated that, in routine clinical practice in industrialized
countries, the risk of AIDS/death was 5 times lower in infants
starting ART before 3 months of age compared with those whose
treatment was deferred, and the difference was significant until
the age of 60 months [3]. Several reports previously demon-
strated that early initiation of treatment and low-baseline VL
were significant predictors of long-term VS [10–12]. In this
article, we report that early initiation of cART was associated
with a lower VL peak despite similar baseline VL. Moreover, we
showed that the virological response was more rapid when
cART was started before 3 months of age. There was a significant
correlation between the age at treatment initiation and the
zenith VL in this latter group, suggesting that the sooner the
treatment is started, the better the virological control. This
observation is important, because VL peak may be correlated
with the establishment of a reservoir of latently infected cells.
Regarding the immunological response to treatment, we
observed that the decrease of CD4 cell count was less pronounced
and the CD4 percentages were higher in the early-treament group
until 12 months of age than in the deferred-treatment group.
However, the CD4 percentages remained significantly lower in all
groups of HIV-infected infants than in HEU controls up to the
age of 2 years.
In this report, the better immunological and virological
evolution observed in the early-treatment group compared with
the deferred-treatment group was no longer detectable by age
12 months, possibly because of lack of power due to sample size.
However, it is possible that the functional competences of CD4
cells are influenced by early initiation of therapy and may
maintain an impact on the clinical outcome after the age of
12 months.
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To limit potential selection and information biases, the
study included HIV-infected infants prospectively followed
from birth to exclude the few long-term nonprogressor
children diagnosed later. We analyzed only infants who re-
ceived cART as first treatment before AIDS developed to
evaluate response to cART in asymptomatic children. The
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Figure 1. Comparison of immunological and virological evolution according to age at treatment initiation. A, Evolution of CD4 percentage in human
immunodeficiency virus (HIV)–infected infants according to age at treatment initiation and in HIV-exposed uninfected infants (HEU). B, Evolution of viral
load (VL) from birth in different groups according to age at treatment initiation. C, Kaplan-Meier survival analysis: time to attaining undetectable
VL (VL ,500 copies/mL) from the time of treatment initiation according to age at treatment initiation.
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2 groups did not differ significantly for the type of first cART
regimen used.
In conclusion, this analysis of the EIC study indicates
that cART initiated before the age of 3 months, in addition to
the strong and durable impact on the clinical outcome pre-
viously described, results in more rapid control of early
virological replication and preservation of CD4 lymphocytes
up to age 12 months compared with deferred treatment. After
the age of 12 months, immunovirological outcomes did not
differ significantly between the groups. Because early initia-
tion of treatment in HIV vertically infected infants is now
recommended in all guidelines, efforts should be made to
establish the diagnosis of infection as soon as possible after
birth.
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